We validated this assay through assessment of MET inhibitor-treated preclinical models, peptide blocking experiments to demonstrate specificity, and concordance with corresponding measurements from the same specimens using a previously validated sandwich immunoassay of tumor lysates. This evidence concerns the gene MET and neoplasm.